BGB-43395
BGB-43395-302
Phase 3 small_molecule active
Quick answer
BGB-43395 for HR+/HER2- Breast Cancer is a Phase 3 program (small_molecule) at BeOne Medicines with 1 ClinicalTrials.gov record(s).
Program details
- Company
- BeOne Medicines
- Indication
- HR+/HER2- Breast Cancer
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active